Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors (SMART101-HV1)

Smart Immune

Status

Enrolling

Conditions

Healthy Volunteers

Treatments

Procedure: Collection of mobilized hematopoietic stem cells (apheresis products) from healthy volunteers

Study type

Interventional

Funder types

Industry

Identifiers

NCT05118113

SI101-HV1

Details and patient eligibility

About

The purpose of this study is to finalise the development of a process for the production of T-cell progenitor cells.

Enrollment

14 estimated patients

Sex

Male

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy donors, men aged 18 to 40 years.
Body weight ≥ 65 kg with a body mass index (BMI) calculated by weight in kg/(height in m)² of 20 to 30 kg/m² at screening.
Informed consent form signed and dated prior to any study-specific screening procedure.
Health status judged by the investigator to be compatible with participation in the study based on medical history, results of physical examination, results of biological laboratory tests (cell blood count including RBC, hematocrit, hemoglobin, reticulocytes, WBC, platelet, PT, aPTT, CRP, fasting blood glucose, ionogram (Na+, K+, Cl-, HCO3-), creatinine, creatinine clearance by Cockcroft, albumin, total protein, total bilirubin, AST, ALT, ALP, GGT), vital signs measurements and 12-lead ECG. All results should be normal or, if out of range, clinically insignificant in the judgement of the investigator.
Venous capital compatible with leukapheresis
Have a high probability of complying with and completing the study.
Be affiliated with a Social Security scheme

Exclusion criteria

Any cardiovascular (e.g. heart failure), hepatic, renal, respiratory (e.g. asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidemia), immunological, dermatological, haematological (including hemoglobinopathy), neurological, psychiatric disorder or any history of allergy to a drug.
State of acute illness (e.g., vomiting, fever, diarrhea) within 7 days prior to the first day of the study.
History of drug abuse in the year preceding the first day of the study.
History of alcoholism in the year prior to day 1 defined as consumption of more than 3 standard drinks/day (30 g/day) or 15 standard drinks/week (150 g/week) or less than two non-alcoholic days each week, or more than 5 standard drinks (50 g) on a single occasion.
Any contra-indication to filgrastim
Positive serological results for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, syphilis and/or human T-lymphotropic virus (HTLV).
Positive urine drug tests (methadone, barbiturates, benzodiazepines, tricyclic antidepressants, cocaine, cannabinoids, morphine, amphetamines and methamphetamines, including 3,4-methylenedioxy-N-methylamphetamine [MDMA]).
Laboratory workup including blood count, fasting blood glucose, blood ionogram, creatinine, AST, ALT, gamma GT, alkaline phosphatase, total bilirubin, CRP, PT, aPTT incompatible with leukapheresis protocol.
Use of any experimental drug within 30 days prior to inclusion.
Use of any prescription or over-the-counter medication within 5 times the elimination half-life prior to inclusion. However, any prescribed medication that may interfere with the study objectives must be discontinued for at least 30 days.